The PLATFORM trial showed that, in patients with stable chest pain, coronary CT angiography (CCTA) plus estimation of fractional flow reserve (FFRCT) can be used safely and effectively to guide care over 90 days. Now, the PLATFORM investigators report that this strategy can reduce costs compared with usual care over 1-year follow-up. In total, 581 of the 584 patients with stable chest pain enrolled into the trial completed the 1-year follow-up. In patients with planned invasive coronary angiography, care guided by CCTA and selective FFRCT was associated with 33% lower costs, and equivalent quality-of-life and clinical outcomes, compared with usual care.